Choosing an appropriate neutralizing antibody assay format: a case study in parallel method development of cell-based and competitive ligand-binding neutralizing antibody assays
The 2019 FDA Immunogenicity Guidance, and Wu, et. al., recommend using a cellbased assay format for neutralizing antibody (NAb) assays when a therapeutic has a cell-based mechanism of action (MoA).